Home » Archives by category » Guidelines-Consensus Statements
Expert consensus on the rational clinical use of proprotein  convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Abstract Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia. These fully human monoclonal antibodies selectively block PCSK9, thus permitting the low-density lipoprotein (LDL) receptor to effectively recycle to the surface of liver […]

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Calculation of the possibility of Familial Hypercholesterolemia using the Dutch criteria:

Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease.

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Calculation of the possibility of Familial Hypercholesterolemia using the Dutch criteria:

ESC 2007 – Guidelines

Review European guidelines on cardiovascular disease prevention in clinical practice: Executive summary www.avtokum.com/ http://senordecor.com.ua/